Adverse Events Seen With JAK Inhibitors for Myelofibrosis


The JAK inhibitors approved for myelofibrosis have common side effects of cytopenias and gastrointestinal issues, with additional risks of weight gain and cardiac effects and diarrhea; momelotinib and pacritinib show improved tolerability compared to earlier JAK inhibitors.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.